Pharvaris (PHVS) Stock Price, News & Analysis

Company Overview

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks. The program is designed to provide patients with an oral alternative to currently available injectable or infused therapies.

The company has conducted clinical development activities in the United States, Europe and other international markets. Pharvaris’ leadership team includes Chief Executive Officer Berndt Modig, who has experience in the biotechnology and pharmaceutical industries. Deucrictibant remains an investigational product, and Pharvaris’ development programs are subject to the review and approval of regulatory authorities.

Key Stats

• Today's Range: $37.00 to $38.38
• 50-Day Range: $32.25 to $38.86
• 52-Week Range: $20.65 to $43.25
• Volume: 825,364 shs
• Average Volume: 406,328 shs
• Market Capitalization: $2.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.87
• Consensus Rating: Moderate Buy

Pharvaris Stock Analysis - MarketRank™

Pharvaris scored higher than 72% of companies evaluated by MarketBeat, and ranked 207th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Pharvaris has a consensus price target of $59.87, representing about 59.4% upside from its current price of $37.55.

Amount of Analyst Coverage

Pharvaris has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharvaris are expected to grow in the coming year, from ($3.12) to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharvaris is -12.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharvaris is -12.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pharvaris has a P/B Ratio of 7.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.75% of the float of Pharvaris has been sold short.

Short Interest Ratio / Days to Cover

Pharvaris has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharvaris has recently increased by 21.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharvaris does not currently pay a dividend.

Dividend Growth

Pharvaris does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.48

News Sentiment

Pharvaris has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for Pharvaris this week, compared to 6 articles on an average week.

Search Interest

13 people have searched for PHVS on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

13 people have added Pharvaris to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,892,286.00 in company stock.

Percentage Held by Institutions

Pharvaris has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/16/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/16/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PHVS
• CIK: 1830487
• Web: www.pharvaris.com
• Phone: 31-71-203-6410
• Fax: N/A
• Employees: 148
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Pharvaris: $59.87
• High Price Target: $79.00
• Low Price Target: $30.00
• Potential Upside/Downside: +59.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.40%
• Return on Assets: -56.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.94
• Quick Ratio: 11.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.71 per share
• Price / Book: 7.97

Miscellaneous

• Outstanding Shares: 65,410,000
• Free Float: N/A
• Market Cap: $2.46 billion
• Optionable: Not Optionable
• Beta: -2.33